Ratings Syntara Limited

Equities

SNT

AU0000312480

End-of-day quote Australian S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
0.044 ^AUD	+25.71%		+46.67%	+120.00%

Jun. 13	Transcript : Syntara Limited Presents at MST Access 'Hidden Gems in Life Sciences' Webinar, Jun-13-2024 02:30 PM
Apr. 30	Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in debt and has limited leeway for investment
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SYNTARA LIMITED	+120.00%	35.69M	C
ELI LILLY AND COMPANY	+62.66%	854B	C+
NOVO NORDISK A/S	+40.42%	636B	B
JOHNSON & JOHNSON	-4.37%	361B	C+
MERCK & CO., INC.	+17.16%	324B	B-
ABBVIE INC.	+9.87%	301B	C+
ASTRAZENECA PLC	+15.66%	247B	B+
ROCHE HOLDING AG	+4.21%	230B	A+
NOVARTIS AG	+17.90%	228B	B-
AMGEN INC.	+14.86%	177B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes